Mucoadhesive amphiphilic methacrylic copolymer-functionalized poly(ε-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine

Journal of Biomedical Nanotechnology

Volumn 11, Issue 8, 2014, Pages 1472-1481

  Fonseca, Francisco N ^a   Betti, Andresa H ^a   Carvalho, Flávia C ^b   Gremião, Maria P D ^b   Dimer, Frantiescoli A ^a   Guterres, Sílvia S ^a   Tebaldi, Marli L ^a   Rates, Stela M K ^a   Pohlmann, Adriana R ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Methacrylic copolymer; Nanocapsule; Nose to Brain delivery; Olanzapine; Poly( caprolactone); Schizophrenia

Indexed keywords

DISEASES; DRUG PRODUCTS; NANOCAPSULES; PARTICLE SIZE; TARGETED DRUG DELIVERY;

BRAIN DELIVERY; BRAIN DRUG DELIVERIES; CAPROLACTONE; CENTRAL NERVOUS SYSTEMS; OLANZAPINE; PARTICLE CONCENTRATIONS; POLY (EPSILONCAPROLACTONE); SCHIZOPHRENIA;

CONTROLLED DRUG DELIVERY;

APOMORPHINE; MUCIN; NANOCAPSULE; OLANZAPINE; POLYCAPROLACTONE; BENZODIAZEPINE DERIVATIVE; METHACRYLIC ACID DERIVATIVE; NEUROLEPTIC AGENT; POLYESTER; SURFACTANT;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; MUCOADHESION; NONHUMAN; NOSE MUCOSA; NOSE TO BRAIN DELIVERY; PARTICLE SIZE; PREPULSE INHIBITION; RAT; REPEATED DRUG DOSE; SENSORY GATING; ANIMAL; BRAIN; CHEMISTRY; DIFFUSION; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; SCHIZOPHRENIA; TREATMENT OUTCOME; ULTRASTRUCTURE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; DIFFUSION; METHACRYLATES; MUCINS; NANOCAPSULES; PARTICLE SIZE; POLYESTERS; RATS; SCHIZOPHRENIA; SURFACE-ACTIVE AGENTS; TREATMENT OUTCOME;

EID: 84919912984     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2078     Document Type: Article

References (43)

1. A. Misra, S. Ganesh, A. Shahiwala, and S. P. Shah, Drug delivery to the central nervous system: A review. J. Pharm. Pharm. Sci. 6, 252 (2003).
2. M. I. Alam, S. Beg, A. Samad, S. Baboota, K. Kohli, J. Ali, A. Ahuja, and M. Akbar, Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40, 385 (2010).
3. A. G. de Boer and P. J. Gaillard, Drug targeting to the brain. Annu. Delivered by Publishing Technology IP: 203.56.241.128 On: Wed,Copyright: American Rev. Pharmacol. Toxicol. 47, 323 (2007).
4. S. Bahadur and K. Pathak, Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Deliv. 9, 19 (2012).
5. Y. Chugh, P. Kapoor, and A. K. Kapoor, Intranasal drug delivery: A novel approach. Otolaryngol. Head Neck Surg. 61, 90 (2009).
6. L. Shah, S. Yadav, and M. Amiji, Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv. Transl. Res. 3, 336 (2013).
7. L. Illum, Nasal drug delivery-possibilities, problems and solutions. J. Control. Release 87, 187 (2003).
8. S. Talegaonkar and P. R. Mishra, Intranasal delivery: An approach to bypass the blood brain barrier. Indian J. Pharmacol. 36, 140 (2004).
9. M. I. Ugwoke, R. U. Agu, N. Verbeke, and R. Kinget, Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug. Deliv. Rev. 57, 1640 (2005).
10. F. C. Carvalho, M. L. Campos, R. G. Peccinini, and M. P. D. Gremião, Nasal administration of liquid crystal precursor mucoadhesive vehicle as an alternative antiretroviral therapy. Eur. J. Pharm. Biopharm. 84, 219 (2013).
11. F. C. Carvalho, M. S. Barbi, V. H. V. Sarmento, L. A. Chiavacci, F. M. Netto, and M. P. D. Gremião, Surfactant systems for nasal zidovudine delivery: Structural, rheological and mucoadhesive properties. J. Pharm. Pharmacol. 62, 430 (2010).
12. L. R. Hanson and W. H. Frey, Intranasal delivery bypasses the bloodbrain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience 9, S5 (2008).
13. M. Chaturvedi, M. Kumar, and K. Pathak, A review on mucoadhesive polymer used in nasal drug delivery system. J. Adv. Pharm. Technol. Res. 2, 215 (2013).
14. V. Grabovac, D. Guggi, and A. Bernkop-Schnürch, Comparison of the mucoadhesive properties of various polymers. Adv. Drug. Deliv. Rev. 57, 1713 (2005).
15. A. Kumari, S. K. Yadav, and S. C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 75, 1 (2010).
16. A. Mistry, S. Stolnik, and L. Illum, Nanoparticles for direct nose-tobrain delivery of drugs. Int. J. Pharm. 379, 146 (2009).
17. K. Nagpal, S. K. Singh, and D. N. Mishra, Drug targeting to brain: A systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin. Drug Deliv. 10, 927 (2013).
18. N. Csaba, M. Garcia-Fuentes, and M. J. Alonso, Nanoparticles for nasal vaccination. Adv. Drug. Deliv. Rev. 61, 140 (2009).
19. E. Penott-Chang, A. Walther, P. Millard, A. Jäger, E. Jäger, A. H. E. Müller, S. S. Guterres, and A. R. Pohlmann, Amphiphilic diblock copolymer and polycaprolactone blends to produce new vesicular nanocarriers. J. Biomed. Nanotech. 8, 272 (2012).
20. F. S. Poletto, R. P. Silveira, L. A. Fiel, B. Donida, M. Rizzi, S. S. Guterres, and A. R. Pohlmann, Size-control of poly(ε-caprolactone) nanospheres by the interface effect of ethanol on the primary emulsion droplets. J. Nanosci. Nanotechnol. 9, 4933 (2009).
21. D. Quintanar-Guerrero, R. Villalobos-García, E. Alvarez-Colín, and J. M. Cornejo-Bravo, In vitro evaluation of the bioadhesive properties of hydrophobic polybasic gels containing N,Ndimethylaminoethyl methacrylate-co-methyl methacrylate. Biomaterials 22, 957 (2001).
22. N. Bhana and C. M. Perry, Olanzapine: A review of its use in the treatment of bipolar i disorder. CNS drugs 15, 871 (2001).
23. F. A. Dimer, M. Ortiz, C. S. Pase, K. Roversi, R. B. Friedrich, A. R. Pohlmann, M. E. Burger, and S. S. Guterres, Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects. J. Biomed. Nanotechnol. 10, 1 (2014).
24. S. Kapur, R. B. Zipursky, and G. Remington, Clinical and theoretical implications of 5-HT 2 and D 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286 (1999).
25. L. Li, Y. Du, N. Li, X. Wu, and Y. Wu, Top-down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci. Biobehav. Rev. 33, 1157 (2009).
26. M. Koch, Clinical relevance of animal models in schizophrenia. Suppl. Clin. Neurophysiol. 62, 113 (2013).
27. J. Li, T.-T. Jiang, J.-N. Shen, and H.-M. Ruan, Preparation and characterization of PMMA and its derivative via RAFT technique in the presence of disulfide as a source of chain transfer agent. J. Memb. Separ. Tech. 1, 117 (2012).
28. O. Lieleg, I. Vladescu, and K. Ribbeck, Characterization of particle translocation through mucin hydrogels. Biophys. J. 98, 1782 (2010).
29. F. A. Dimer, A. R. Pohlmann, and S. S. Guterres, Characterization of rheology and release profiles of olanzapine-loaded lipid-core nanocapsules in thermosensitive hydrogel. J. Nanosci. Nanotechnol. 13, 8144 (2013).
30. L. J. Dusci, L. Peter Hackett, L. M. Fellows, and K. F. Ilett, Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J. Chromatogr. B 773, 191 (2002).
31. J. Chiefari, Y. K. B. Chong, F. Ercole, J. Krstina, J. Jeffery, T. P. T. Le, R. T. A. Mayadunne, G. F. Meijs, C. L. Moad, G. Moad, E. Rizzardo, S. H. Thang, and C. South, Living free-radical polymerization by reversible addition-fragmentation chain transfer : The RAFT process. Macromolecules 31, 5559 (1998).
32. Y. L. Luo, J. F. Yuan, X. J. Liu, and Q. Y. Gao, Self-assembled polyion complex micelles based on PVP-b -PAMPS and PVP-b-PDMAEMA for drug delivery. J. Bioact. Compat. Polym. 25, 292 (2010).
33. P. V. D. Wetering, N. J. Zuidam, M. J. van Steenbergen, O. A. G. J. van der Houwen, W. J. M. Underberg, and W. E. Hennink, A mechanistic study of the hydrolytic stability of poly(2-(dimethylamino) ethyl methacrylate). Macromolecules 31, 8063 (1998).
34. P. R. Majhi, R. R. Ganta, R. P. Vanam, E. Seyrek, K. Giger, and P. L. Dubin, Electrostatically driven protein aggregation: Betalactoglobulin at low ionic strength. Langmuir 22, 9150 (2006).
35. F. C. Carvalho, M. L. Bruschi, R. C. Evangelista, and G. M. P. D., Mucoadhesive drug delivery systems. Braz. J. Pharm. Sci. 46, 1 (2010).
36. V. V. Khutoryanskiy, Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci. 17, 748 (2011).
37. R. W. Korsmeyer, R. Gumy, E. Doelker, P. Buri, and N. A. Peppas, Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 15, 25 (1983).
38. K. Bueno, M. D. Adorne, D. S. Jornada, F. N. da Fonseca, S. S. Guterres, and A. R. Pohlmann, In vivo gastroprotective effect of nanoparticles: Influence of chemical composition and volume fraction. Curr. Pharm. Des. 19, 7294 (2013).
39. U. Seju, A. Kumar, and K. K. Sawant, Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater. 7, 4169 (2011).
40. R. D. Porsolt, P. C. Moser, and V. Castagne, Behavioral indices in antipsychotic drug discovery. J. Pharmacol. Exp. Ther. 333, 632 (2010).
41. C. A. Jones, D. J. G. Watson, and K. C. F. Fone, Animal models of schizophrenia. Br. J. Pharmacol. 164, 1162 (2011).
42. T. A. Sonia and C. P. Sharma, In vitro evaluation of quaternized polydimethylaminoethylmethacrylate sub-microparticles for oral insulin delivery. J. Biomater. Appl. 28, 62 (2013).
43. J. W. Young, S. B. Powell, C. N. Scott, X. Zhou, and M. A. Geyer, The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav. Brain Res. 222, 183 (2012).